In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its ...

A more effective vaccine technology may be on the horizon. In a new study in mice, researchers from the University of ...

As new variants of COVID 19 keep appearing, many people have expressed concern over whether these variants can be detected by ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) ...

Even though Sri Lanka has been acknowledged as a country with a satisfactory literacy rate, time has come to question whether the average Sri Lankan also falls into the categories of literate, ...

Centenarians get asked, “What’s your secret?” The honest answer is “good genes and good luck.” But for men who have reached old, old age, a fair addition might be “plus a functioning prostate.” This ...

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET 1 ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...